- Home
- SRCE vs VRDN Comparison
SRCE vs VRDN Comparison
Compare SRCE & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRCE | VRDN |
|---|---|---|
| Founded | 1863 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SRCE | VRDN |
|---|---|---|
| Price | $65.48 | $32.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $71.25 | $39.73 |
| AVG Volume (30 Days) | 78.2K | ★ 1.6M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 14.53 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | ★ $405,363,000.00 | $70,789,000.00 |
| Revenue This Year | $18.73 | $26,477.48 |
| Revenue Next Year | $2.28 | $6.23 |
| P/E Ratio | $10.91 | ★ N/A |
| Revenue Growth | 9.59 | ★ 23340.07 |
| 52 Week Low | $52.14 | $9.90 |
| 52 Week High | $67.77 | $33.34 |
Technical Indicators
Market Signals| Indicator | SRCE | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 65.20 |
| Support Level | $62.93 | $31.11 |
| Resistance Level | $67.00 | $33.29 |
| Average True Range (ATR) | 1.41 | 1.23 |
| MACD | 0.29 | -0.17 |
| Stochastic Oscillator | 77.55 | 69.57 |
Price Performance
Historical ComparisonAbout SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).